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Deletion mutants of a synthetic human erythropoietin-cDNA were transiently expressed in COS-7 cells and products analyzed using Western blots 
and a cell proliferation assay. Only two mutants with deletions affecting the N-terminal portion and the amino acid sequence 115-121 displayed 
biological activity. The exchange of hydrophilic, charged amino acids by alanine in two potential u-helical regions, the internal amino acid sequence 
102-106 and the C-terminal sequence lS4-159, causes a 2-11-fold loss of activity. The results suggest hat both regions are involved in either 
maintaining the active structure of the hormone or interacting with the receptor. 
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1. I~R~DUCTION 
The proliferation and differentiation of erythroid 
progenitor cells are regulated by the glycoprotein 
hormone erythropoietin [ 11. Although the recombinant 
protein is available and in clinical use for some years 
many questions concerning the molecular mechanism of 
EPO’s action remain to be answered. Further under- 
standing of its function may be gained from the analysis 
of the interaction with the EPO-receptor and the signal 
induction pathways induced. 
export and biological activity of the products in most 
cases [9,10,1 I]. A study on the region between amino 
acids 99-129 provides evidence that changes to residues 
99-l 10 lead to an inactivation of EPO [ 111. 
A number of studies have shown that the glycosyla- 
tion, which accounts for 40% of the molecular mass, is 
responsible for the in vivo stability, cellular processing 
and secretion [2,3,4,5]. The protein portion of the mole- 
cule is essential for interaction with the receptor. Infor- 
mation available on the location of the receptor binding 
site has been generated by strategies involving anti-pep- 
tide antibodies [6,7,8], mutational analysis [9,10,11] and 
by comparing the sequences of EPO genes from differ- 
ent species [12]. Extensive studies with anti-peptide anti- 
bodies show that only those which are derived from 
peptides covering an internal region (amino acids 99- 
1 19; 11 l-129) and the C-terminal portion (amino acids 
152-I 66) are able to neutralize the biological activity of 
EPO [7,8]. Deletion of amino acids in regions predicted 
to have a a-helical structure result in the expression of 
proteins which are not exported by the cells, whereas 
mutations within the interhelical oops do not affect the 
We have further characterized the role of regions 
predicted to be functionally important and shown that 
deletions, even single amino acid substitutions in the 
C-terminus and residues 102-106, lead to a loss or sig- 
nificant reduction of the biological activity suggesting 
that these regions are directly involved in the binding of 
EPO to its receptor. Moreover, our results exclude an 
N-terminal region and the amino acids 115-l 21 as func- 
tionally active portions of the molecule. 
2. MATERIAL AND METHODS 
2.1. EPO gene synthesis 
A synthetic human EPO gene was generated by a chemoenzymatic 
strategy. 
The amino acid sequence was transferred into a DNA-sequence by 
a computer program creating as many restriction sites as possible 
without changing the amino acid composition. The coding region was 
assembled by the sequential ligation of eight blocks consisting of a pair 
of oligonucleotides each. The oligonucleotides were designed to have 
complementary regions at their 3’ termini and compatible restriction 
sites to join the blocks. After annealing the oligonucleotide pairs they 
were filled in with Klenow-polymerase to give full-length double 
stranded products. Individual blocks were cloned, sequenced and li- 
gated using standard procedures [13]. 
2.2. Deletion mutagenesis and site-directed mutagenesis 
*Corresponding author. Fax: (44) (381) 45-5383. 
Abbreviations: Epo, erythropoietin; GM-CSF, granulocyte-macro- 
phage colony-st~ulating factor. 
The gene synthesis trategy used provided enough possibilities for 
deletions in the entire coding region. The deletions were introduced 
using restriction enzymes. The products were subcloned into the plas- 
mid pucl9. Site-directed mutagenesis was carried out with a Muta- 
Gene Ml3 in vitro Mutagenesis Kit (Biorad, Richmond, CA) accord- 
ing to a method published by Kunkel[14]. The presence of all muta- 
tions was confirmed by sequencing all constructs with the dideoxy 
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chain termination method [15] and a sequencing kit supplied by USB 
(Cleveland, OH). 
2.3. ~xpressio~ vector cortstructs 
The human EPG mutants were s&cloned into the EcoRI restriction 
site of the plasmid pSVSPORT1 (Gibco, BRL) containing the SV40 
origin of replication, earIy transcriptional promoter, small t-intron 
and polyadenylation signals (Fig. 1). The orientation of the inserts was 
confirmed by restriction-mapping. Plasmid DNA was prepared by 
CsCl-gradient centrifugation followed by two extractions with water- 
saturated iso~yI~coho1. 
2.4. Transfection of EPO and its analogues 
The DNA constructs were transfected into COS-7 cells. COS-7 cells 
were grown to 80% confluence in Dulbecco’s Modified Eagle’s me- 
dium (DMEM) containing 20 mM HEPES and supplemented with 
10% fetal calf serum (FCS). Usually, 20 #g C&l-purified non-linear- 
ized plas~d-DNA and 20 pg son&ted salmon sperm DNA were 
combined with 4 x 10’ cells in 800 ~1 medium supplemented with 10% 
FCS. The electroporation was performed with a BioRadGenePuher 
[16]. A capacitance of 960 ,uF and a voltage of 250 V were found to 
produce the highest transfection efficiency. Transfections with the 
vector pSVSPORT1 were included as controls. The single cell suspen- 
sion was plated in growth medium immediately post transfection. 
After 24 h of growth as adherent monolayers them~ium was replaced 
by FCS-free medium and the cells incubated for another 24 h. The 
conditioned medium was harvested and used for the EPO assays. 
2.5. Detection of mutant EPO proteins 
EPO-protein was detected by Western blots using a monoclonal 
antibody directed against he NH,-terminal portion of the amino acid 
sequence supplied by Medac (Hamburg). EPO-containing COS-cell 
supernatants were size-fractioned by SDS-PAGE using the buffer 
system described by Laemmli [17j and 10% gels. For Western blot 
analysis, proteins were transferred to a 0.2 mm membrane (Hybond- 
ECL, Amersham) by semi-dry blotting. Non-specific binding sites on 
the filter were blocked by incubation in PBS/O.l% Tween (PBS-T). 
Blots were incubated with the anti-EPO-antibody (10 pg) in PBS-T 
containing 1% BSA for 2 h. After washing with PBS-T and incubation 
with a horseradish peroxidase labelled anti-mouse Ig antibody (Amer- 
sham, 1:5000 in PBS-T/l% BSA) for one hour, the blots were washed 
with PBS and developed with the ECL-system purchased from Amer- 
sham. The bands were scanned by an imaging densitometer (GS-670, 
Biorad). Several exposures were taken to ensure that the signals were 
in the linear range of film response. The quantification of EPO-protein 
was performed by the comparative analysis with pure recombinant 
EPO. 
2.6. Stimulation of hematopoietic cell proliferation 
The biological activity of EPO mutant proteins was measured by an 
in vitro bioassay using the EPO-sensitive cell line TF-1. This human 
erythroleukemic cell line was established by Ritamura et al. [18] and 
kindly supplied by W. Gstertag, Hein~ch~Pette-Institut, Hamburg. 
The cells were cultivated in RPM1 1640 medium (Gibco) suppie- 
mented with 10% FCS and 7.5 @ml GM-CSF. Exponentially grow- 
ing cells were washed free of growth factor, maintained 24 h without 
GM-CSF and exposed to dilutions of the conditioned COS-cell super- 
natants for an additional 48 h. The proliferation of the cells was 
measured with the MTT reduction assay essentially as described by 
Mosmann [19]. The activity of the mutant proteins was determined 
after Western blot q~t~~tion using re~mbinant human EPO with 
known specmc activity as a standard. 
3. RESULTS 
A synthetic EPO-cDNA was constructed by a chemo- 
enzymatical approach. The strategy involved the intro- 
duction of additional restriction sites, which were used 
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Fig. 1. Expression vector pSVEP0. 
to generate a series of deletion mutants. Fig. 2 depicts 
the structure of the mature human EPO-molecule and 
shows the location of the deletions and the ammo acid 
substitutions as well as the predicted a-helices in its 
secondary structure. 
The EPO-analogues were designed with regard to 
earlier reports of mutational analysis [lO,l I], experi- 
ments with anti-peptide antibodies [6,7,8,24] and evolu- 
tionary considerations [121. 
The ammo acids deleted or changed are shown in 
Table I. Besides the deletion in EPOd all mu~tions are 
located within one of the four predicted a-helices. These 
a-helices are thought to be critical for the tertiary struc- 
ture of growth factors and hence may represent the 
receptor-binding portion of several hematopoietic 
growth factors, hormones and cytokines [20]. The dele- 
tion of the EPOd mutant is located in the loop joining 
a-helices C and D. Peptides covering this region were 
shown to induce antibodies which are able to neutralize 
EPO’s activity [7]. 
After subcloning the constructs into the expression 
vector shown in Fig. 1 the cDNA’s were transiently 
expressed in COS-7 cells. By analyzing the su~~atan~ 
Table I 
Erythropoietin analogues created by deletion and site-directed mut- 
agenesis 
Construct Amino acids deleted or changed a-Helix 
position* 
EPOWT 
EPG” 
EPOb 
EPG’ 
EPGd 
EPO” 
EPO’03 
EPOlw 
EPO’” 
EP0’59 
_ 
Gln’3-Arg’4-‘Qr’5-Leui6-Leu’7 
Gln65-Gly66-Leu67-Aiab’-~u69 
Leu'02_Arg'~~_~r'~-4_Leu'05-~r'ffi 
G~“~_Lys”4Glu”7_A]a*‘*_Ile’19_Ser’to_ 
Pro”’ 
Lys’54-Leu 1ss_Tyr'5h_Thr'57_G]y'*8-Gly'5g 
Arg”’ + Ala”’ 
ThrlM + Alalo 
Lys’% + Ala’” 
GIu*~~ -+ Alals9 
_ 
A 
B 
C 
D 
C 
C 
D 
D 
*Predicted by Bazan [20], see Fig. 2. 
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Fig. 2. Structural features of the human EPO-molecule and location of the investigated eletions/amino acid substitutions. (I) Primary structure 
of the mature human EPO-molecule comprising 165 amino acids; N- and O-linked glycosylation sites are shown by circles; the dashed lines represent 
the disulphide bonds. (II) Rectangles how the location of the predicted a-helices. (III) Location of deletions and amino acid substitutions that 
were introduced into wild-type-EPO (WI-EPO). 
in Western blots we could show that all the recombinant 
proteins except EPO” were synthesized by the COS cells 
(Fig. 3). In the case of EPO” (deletion of amino acids 
102-106), protein was not detectable in lysed cells (re- 
sults not shown) as well as supernatants. In comparison, 
Chern et al. [l l] report the inability of COS cells to 
synthesize detectable amounts of EPO after transfection 
with mutants affecting the amino acids 99-108. The 
quantification of the Western blot signals with the help 
of a standard and densitometric scanning revealed se- 
cretion levels in the range of 15-24 @ml. The molecu- 
lar weight of the proteins was in the expected range with 
a very similar molecular weight heterogeneity, indicat- 
ing a normal post-translational modification of the 
products. The supernatants were assayed for their abil- 
ity to stimulate growth of the EPO-responsive cell line 
TF-1, as well as their content of immunoreactive pro- 
tein. The results presented in Table II, indicate that the 
wild-type cDNA was efficiently expressed and secreted. 
Only two of five EPO-analogues with amino acid dele- 
tions, EPO” (N-terminal amino acids 13-17) and EPOd 
(internal amino acids 115-121), were found to be active. 
The deletions of C-terminal amino acids 154-159 
1 2 3 4 5 6 7 6 9 10 
30 kDa > 
Fig. 3. Western blot analysis of recombinant human EPO-analogues 
in COS-‘l-cell supematants. Recombinant EPO and the analogues 
were detected by Western blotting with an anti-EPO-antibody and 
display the normal size of fully glycosylated EPO. All COS-cell super- 
natants expressed the transfected EPO gene except EPO’. Lane 
1 = EPO”‘; lane 2 = EPO”‘; lane 3 = EPOI”; lane 4 = EPO’“; lane 
5 = EPO’= 1 , ane 6 = EPO”; lane 7 = EPOb; lane 8 = EPO’; lane 
9 = EPOd; lane 10 = EPO’. 
(EPOe) and two internal sequences (amino acids 65-69/ 
EPOb; amino acids 102-106/EPO”) are obviously delete- 
rious for the expression of an active protein. However, 
the amino acid substitutions affecting the same a-helical 
regions as the deletions in EPO” and EPO”, resulted in 
detectable, although significantly reduced, activity. The 
exchange of the hydrophilic amino acids residues 
Arg 
103, TblO6, Lys154 and G~u’~~ with the neutral amino 
acid alanine causes a 2-11-fold loss of relative specific 
activity. 
4. DISCUSSION 
The aim of this study was to characterize regions of 
the EPO-molecule which are thought to participate in 
the interaction with the EPO-receptor and to identify 
critical amino acid residues involved. In initial experi- 
ments internal deletions of 5-7 amino acids were intro- 
duced into the wild-type EPO to reveal functionally 
important domains. Four of the five deletion mutants 
were effectively expressed as shown by Western blot 
analysis, but only two of them displayed biological ac- 
tivity. 
A mutant with a deletion located in the N-terminal 
part (EPOa) had nearly the same biological activity as 
the wild-type EPO, confirming the observation that an- 
tibodies specific for this region do not neutralize the 
activity of the hormone [6,21]. Another mutant (EPOd 
lacking amino acids 115121) with the deletion in the 
region which is predicted to join a-helices C and D [20] 
displayed slightly decreased activity. Similar results 
were shown by Boissel et al. [9] analyzing EPO-mutants 
with a deletion of the amino acids 11 l-l 19 or an inser- 
tion of a myc epitope after Lys116, and by Chern et al. 
[l l] using sequential alteration of the secondary struc- 
ture defined by the amino acids 12&129. 
135 
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In contrast, any deletions in this study and reported 
by others [9,10,1 l] affecting the a-helical stretches close 
to the C-terminus (helices C, D) were deleterious for 
hormonal activity, probably by causing misfolding of 
the products. The model for the tertiary structure of 
EPO and several other growth factors and hormones 
presented by Bazan [20] would suggest hat the helical 
structure near the C-terminus comprises the receptor 
binding structure. Studies using antipeptide antibodies 
to hydrophilic regions show that antibodies to the C- 
terminal amino acids [8], as well as to different peptides 
covering the amino acids 99-129 [7], are able to neutral- 
ize the bioactivity of EPO. In addition, EPO molecules 
tagged with a hemagglutinin influenza virus epitope or 
a consensus sequence for phosphorylation at the C- 
terminus were inactive [22]. From all data available it 
is evident that the internal and C-terminal regions are 
necessary to maintain a biologically active structure and 
are possibly involved in receptor binding. 
Deletions of amino acids, as well as the binding of 
antibodies can lead to gross structural alterations and 
consequently the inactivation of proteins. Therefore, 
single amino acid changes were introduced into the mol- 
ecule in this study to determine if the exchange of resi- 
dues which are known to be typically involved in recep- 
tor interactions, affected the bioactivity. The residues 
selected for mutagenesis are highly conserved in differ- 
ent EPO-species [12]. Amino acids with hydrophilic, 
charged side chains were replaced by the neutral amino 
acid alanine to minimize alterations in the backbone 
conformation of the recombinant EPO. The lysine resi- 
due at position 154 is predicted to be exposed on the 
surface of helix D which displays conserved sequence 
patterns in a number of cytokines [20,22]. In each case 
a loss of specific activity was observed, with the greatest 
Table II 
Biological activity of Erythropoietin in COS-7-&l supernatants 
Construct Biological activity Relative specific activity 
(U/ml)* (%)** 
EPOwr 3.7 f 0.4 100 
EPO” 3.4 f 0.5 109 
EPOb n.d. _ 
EPO n.d. _ 
EP@ 2.5 + 0.4 88 
EPO’ n.d. _ 
EP@’ 1.2 f 0.3 47 
EP0’06 1.6 f 0.3 41 
EPO’% 0.4 It 0.1 9 
EP0’59 0.8 f 0.2 26 
*Determined by a cell proliferation assay (see Section 2) data ex- 
pressed as means + S.D. (n = 3) 
**Calculated by comparing the quotient of biological activity/im- 
munoreactive protein content for each EPG analogue to the wild type 
EPO. 
n.d. = not detectable. 
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reduction in activity detected in the mutants affecting 
the region close to the C-terminus. 
The data presented here, therefore, indicate the im- 
portant role of the amino acid sequences 102-106 and 
154-l 59 and define single residues within the helices C 
and D, which may be involved in the receptor interac- 
tion of EPO. 
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